ScholarIQanswers from OpenAlex & ORCID
Seiji Niho
ResearcherPublications, citations & collaboration network
Seiji Niho is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Seiji Niho have?
ScholarIQindexed works
Seiji Niho has 398 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Seiji Niho have?
ScholarIQcitation count
Seiji Niho has 7,703 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Seiji Niho?
ScholarIQh-index
Seiji Niho has an h-index of 43 in OpenAlex.
What is the i10-index of Seiji Niho?
ScholarIQi10-index
Seiji Niho has an i10-index of 123 in OpenAlex.
What is the ORCID of Seiji Niho?
ScholarIQorcid
The ORCID for Seiji Niho is on the source record.
What is the OpenAlex record for Seiji Niho?
ScholarIQopenalex
The OpenAlex for Seiji Niho is on the source record.
What are the most-cited papers on Seiji Niho?
ScholarIQmost cited works
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
Yi‐Long Wu, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Fumito Tsuji, R. Linke, Rafael Rosell, J. Corral, Maria Rita Migliorino, Adam Płużański, Eric Sbar, Tao Wang, Jane Liang White, Sashi Nadanaciva, Rickard Sandin, Tony Mok
Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and <i>EGFR</i>-Activating Mutations
Tony Mok, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Min Lee, R. Linke, Rafael Rosell, J. Corral, Maria Rita Migliorino, Adam Płużański, Eric Sbar, Tao Wang, Jane Liang White, Yi‐Long Wu
Therapeutic Priority of the PI3K/AKT/mTOR Pathway in Small Cell Lung Cancers as Revealed by a Comprehensive Genomic Analysis
Shigeki Umemura, Sachiyo Mimaki, Hideki Makinoshima, Satoshi Tada, Genichiro Ishii, Hironobu Ohmatsu, Seiji Niho, Kiyotaka Yoh, Shingo Matsumoto, Akiko Takahashi, Masahiro Morise, Yuka Nakamura, Atsushi Ochiai, Kanji Nagai, Reika Iwakawa, Takashi Kohno, Jun Yokota, Yuichiro Ohe, Hiroyasu Esumi, Katsuya Tsuchihara, Kōichi Goto
Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer
Seiji Niho, Hideo Kunitoh, Hiroshi Nokihara, Takeshi Horai, Yukito Ichinose, Toyoaki Hida, Nobuyuki Yamamoto, Masaaki Kawahara, Tetsu Shinkai, Kazuhiko Nakagawa, Kaoru Matsui, Shunichi Negoro, Akira Yokoyama, Shinzoh Kudoh, Katsuyuki Kiura, Kiyoshi Mori, Hiroaki Okamoto, Hiroshi Sakai, Koji Takeda, Soichiro Yokota, Nagahiro Saijo, Masahiro Fukuoka
Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial
Jun Sato, Miyako Satouchi, Shoichi Itoh, Yusuke Okuma, Seiji Niho, Hidenori Mizugaki, Haruyasu Murakami, Yasuhito Fujisaka, Toshiyuki Kozuki, Kenichi Nakamura, Yukari Nagasaka, Mamiko Kawasaki, Tomoaki Yamada, Ryunosuke Machida, Aya Kuchiba, Yuichiro Ohe, Noboru Yamamoto